Analysis of the Effect of Milk Derived Compound Probiotics on Intestinal Flora of Diabetes Mice based on 16S rRNA Sequencing
SHEN Fang1, WANG Yuxing1, JIAERKEN Didaier1, TOLIUHAN Hapula2, NABI Xinhua1*
The purpose of this study was to investigate the mechanism of milk-derived compound probiotics on db/db diabetic mice from the perspective of intestinal flora. Thirty-two db/db diabetic mice were divided into model group, rosiglitazone group, compound probiotics high-dose and low-dose groups, and eight C57BL/ KS mice were used as normal control group. HbA1c (glycosylated hemoglobin, type A1C), TBA (total bile acid), GLP-1 (glucagon-like peptide 1) levels were determined by ELISA. 16S rRNA sequencing was used to analyze the changes of intestinal flora in each group. The results showed that compared with the model group, both high-dose and low-dose compound probiotics could significantly reduce HbA1c and serum TBA, and increase serum GLP1. Compared with the normal group, the intestinal microflora structure of mice in the model group was changed, and the structure of intestinal flora in the compound probiotic group was changed compared with that in the model group. At the genus level, Proteobacteria and Enterobacteriaceae in the model group are enriched. In low dose group norank_f__Lachnospiraceae, Lachnospiraceae_UCG-006, Butyricicoccus and Anaerotruncus are enriched. In compound probiotics high dose group, Escherichia-Shigella, Unclassified_f__Eggerthellaceae, and Family_XIII_ UCG-001 were enriched. Compound probiotics may play a role in the treatment of diabetes by regulating intestinal microflora imbalance in diabetic mice. The specific mechanism needs to be further studied.
CN
EN